MetaADEDB 2.0 @ LMMD
Bleomycin
(WUIABRMSWOKTOF-OCBSMOPSSA-N)
Structure
SMILES
[O-]S(=O)(=O)O.OC[C@@H]1O[C@@H](OC(C(C(=O)NC(C(C(C(=O)NC(C(=O)NCCc2scc(n2)c2scc(n2)C(=O)NCCC[S+](C)C)C(O)C)C)O)C)NC(=O)c2nc(nc(c2C)N)C(CC(=O)N)NCC(C(=O)N)N)c2[nH]cnc2)[C@H]([C@H]([C@@H]1O)O)O[C@H]1O[C@H](CO)[C@H]([C@@H]([C@@H]1O)OC(=O)N)O
Molecular Formula:
C55H85N17O25S4
Molecular Weight:
1512.620
Log P:
-1.8904
Hydrogen Bond Acceptor:
43
Hydrogen Bond Donor:
21
TPSA:
794.66
CAS Number(s):
9041-93-4
Synonym(s)
1.
Bleomycin
2.
BLEO-cell
3.
Blanoxan
4.
Blenoxane
5.
Bleolem
6.
Bleomicina
7.
Bleomycin A(2)
8.
Bleomycin A2
9.
Bleomycin B(2)
10.
Bleomycin B2
11.
Bleomycin Sulfate
12.
Bleomycins
13.
Bleomycinum Mack
14.
Bléomycine Bellon
15.
BLEO cell
16.
BLEOcell
17.
Bellon, Bléomycine
18.
Mack, Bleomycinum
19.
Sulfate, Bleomycin
External Link(s)
MeSHD001761
PubChem Compound72466
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1DermatitisFAERS: 18US FAERS
2Pulmonary toxicityFAERS: 10
Canada Vigilance: 1
Canada Vigilance
OFFSIDES
US FAERS
3HypotensionFAERS: 9US FAERS
4ChillsFAERS: 7US FAERS
5SclerodermaFAERS: 7US FAERS
6White blood cell count decreasedFAERS: 5US FAERS
7NauseaFAERS: 3US FAERS
8PneumoniaFAERS: 3US FAERS
9Product substitution issueFAERS: 3US FAERS
10Respiratory FailureFAERS: 3US FAERS
11Cerebral InfarctionFAERS: 2US FAERS
12Cerebral artery stenosisFAERS: 2US FAERS
13HemiparesisFAERS: 2US FAERS
14HypersensitivityFAERS: 2US FAERS
15HypopituitarismFAERS: 2US FAERS
16Idiopathic Pulmonary FibrosisFAERS: 2US FAERS
17Pulmonary FibrosisFAERS: 2US FAERS
18Therapeutic response unexpected with drug substitutionFAERS: 2US FAERS
19Toxicity to various agentsFAERS: 2US FAERS
20VomitingFAERS: 2US FAERS
21AbscessFAERS: 1US FAERS
22Accidental exposureFAERS: 1US FAERS
23Acute respiratory failureFAERS: 1OFFSIDES
US FAERS
24AngioedemaFAERS: 1US FAERS
25Back PainFAERS: 1US FAERS
26Circumstance or information capable of leading to medication errorFAERS: 1US FAERS
27Cold sweatFAERS: 1US FAERS
28CyanosisFAERS: 1US FAERS
29Drug exposure during pregnancyFAERS: 1US FAERS
30Drug ineffectiveFAERS: 1US FAERS
31Drug label confusionFAERS: 1US FAERS
32Drug toxicityFAERS: 1OFFSIDES
US FAERS
33FatigueFAERS: 1US FAERS
34Febrile NeutropeniaFAERS: 1
Canada Vigilance: 1
Canada Vigilance
OFFSIDES
US FAERS
35HypoxiaFAERS: 1US FAERS
36InfarctionFAERS: 1US FAERS
37Medication ErrorFAERS: 1US FAERS
38MetastasisFAERS: 1US FAERS
39Myocardial InfarctionFAERS: 1US FAERS
40Neutrophil count decreasedFAERS: 1US FAERS
41NoduleFAERS: 1US FAERS
42PallorFAERS: 1US FAERS
43PneumonitisFAERS: 1US FAERS
44PneumothoraxFAERS: 1US FAERS
45Product label issueFAERS: 1US FAERS
46Pulmonary EmbolismFAERS: 1US FAERS
47Restrictive pulmonary diseaseFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
48Serum SicknessFAERS: 1US FAERS
49Skin reactionFAERS: 1US FAERS
50Skin toxicityFAERS: 1OFFSIDES
US FAERS
51Subcutaneous EmphysemaFAERS: 1US FAERS
52Sudden deathFAERS: 1US FAERS
53ThrombosisFAERS: 1US FAERS
54Abdominal rigidityOFFSIDES
55Acute psychosisOFFSIDES
56AdenocarcinomaOFFSIDES
57Alpha 1 foetoprotein decreasedOFFSIDES
58AmenorrheaOFFSIDES
59AmyloidosisOFFSIDES
60AnhidrosisOFFSIDES
61Arterial thrombosisOFFSIDES
62Autoimmune thrombocytopeniaOFFSIDES
63Axillary vein thrombosisOFFSIDES
64Blood parathyroid hormone increasedOFFSIDES
65Bone marrow depressionOFFSIDES
66Bone marrow necrosisOFFSIDES
67Bone painOFFSIDES
68CardiotoxicityOFFSIDES
69Carotid Artery ThrombosisOFFSIDES
70ChondrosarcomaOFFSIDES
71ChoriocarcinomaOFFSIDES
72Conus Medullaris SyndromeOFFSIDES
73DemyelinationOFFSIDES
74Device related infectionOFFSIDES
75Diffuse alveolar damageOFFSIDES
76DiverticulumOFFSIDES
77DysmenorrheaOFFSIDES
78Embolic cerebral infarctionOFFSIDES
79Epstein-Barr virus associated lymphoproliferative disorderOFFSIDES
80Erythema InfectiosumOFFSIDES
81Febrile bone marrow aplasiaOFFSIDES
82FibrinolysisOFFSIDES
83FolliculitisOFFSIDES
84Granulocyte count decreasedOFFSIDES
85HaematotoxicityOFFSIDES
86HemiplegiaOFFSIDES
87HemothoraxOFFSIDES
88Hepatitis BOFFSIDES
89Hilar lymphadenopathyOFFSIDES
90InfectionOFFSIDES
91Injection site infectionOFFSIDES
92Intestinal PerforationOFFSIDES
93Labile blood pressureOFFSIDES
94Leukopenia neonatalOFFSIDES
95LymphomaOFFSIDES
96MalariaOFFSIDES
97Malignant neoplasm of spinal cordOFFSIDES
98Malignant neoplasm progressionOFFSIDES
99MegacolonOFFSIDES
100Microsporum infectionOFFSIDES
101MyelodysplasiaOFFSIDES
102Neutropenic infectionOFFSIDES
103Neutropenic sepsisOFFSIDES
104Neutrophil count abnormalOFFSIDES
105OligohydramniosOFFSIDES
106Ovarian failureOFFSIDES
107Oxygen saturation abnormalOFFSIDES
108Papillary serous endometrial carcinomaOFFSIDES
109ParaparesisOFFSIDES
110PericarditisOFFSIDES
111Peripheral arterial occlusive diseaseOFFSIDES
112Peripheral embolismOFFSIDES
113Pilonidal CystOFFSIDES
114Pneumocystis jiroveci pneumoniaOFFSIDES
115Post procedural hypothyroidismOFFSIDES
116Pseudomonal sepsisOFFSIDES
117Pulmonary function test decreasedOFFSIDES
118Radiation interactionOFFSIDES
119SarcoidosisOFFSIDES
120Senile dementiaOFFSIDES
121Septic ShockOFFSIDES
122Sinus headacheOFFSIDES
123Sinus polypOFFSIDES
124Stem cell transplantOFFSIDES
125ThrombophlebitisOFFSIDES
126ThyroiditisOFFSIDES
127TonsillitisOFFSIDES
128Treatment related secondary malignancyOFFSIDES
129Troponin increasedOFFSIDES
130Upper airway obstructionOFFSIDES
131Vaginal obstructionOFFSIDES
132Venous thrombosis limbOFFSIDES
133kyphosisOFFSIDES
134treatment failureOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120238

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.